Concepedia

Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus

Dean J. Kereiakes, Stephen G. Ellis, Takeshi Kimura, Alexandre Abizaid, Weiying Zhao, Susan Veldhof, Minh-Thien Vu, Zhen Zhang, Yoshinobu Onuma, Bernard Chevalier,

JACC: Cardiovascular Interventions · 2016 · 22 citations · 25 references

DOI

Concepts

References

25

Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents

Ιoannis Iakovou · JAMA · 2005 · 3.1K citations · Full text

, , +12

Checking the Cox model with cumulative sums of martingale-based residuals

D. Y. Lin, L. J. Wei, Z. Ying · Biometrika · 1993 · 1.4K citations

, , +16

Pathological Correlates of Late Drug-Eluting Stent Thrombosis

Aloke V. Finn, Michael Joner, Gaku Nakazawa et al. · Circulation · 2007 · 1.3K citations · Full text

, , +12

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Stephen G. Ellis, Dean J. Kereiakes, D. Christopher Metzger et al. · New England Journal of Medicine · 2015 · 621 citations · Full text

, , +16

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 560 citations · Full text

, , +17